Products
Rolistobart Biosimilar Monoclonal Antibody (ILT3) for Research
Cat No.: GMP-Bios-INN-1375
Anti-LILRB4/CD85K therapeutic antibody (Pre-made Rolistobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Rolistobart (development code MK-0482) is a humanized monoclonal antibody targeting LILRB4. It is developed by Merck Sharp & Dohme LLC for Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1375-1mg | 1mg | 3090 |
| GMP-Bios-INN-1375-10mg | 10mg | |
| GMP-Bios-INN-1375-100mg | 100mg | |
| GMP-Bios-INN-1375-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Rolistobart biosimilar, Whole mAb, Anti-LILRB4/CD85K Antibody: Anti-LILRB4/ILT-3/CD85k/Leukocyte immunoglobulin-like receptor subfamily B member 4 therapeutic antibody |
| INN Name | Rolistobart |
| Target | LILRB4/CD85K |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | na |
